OS Therapies (OSTX) Change in Account Payables (2023 - 2025)
OS Therapies' (OSTX) quarterly Change in Account Payables came in at $6.6 million in Q4 2025, up 6071.13% YoY from $106335.4 in Q4 2024, and up 877.14% on a QoQ basis from $671563.0 in Q3 2025.
OS Therapies (OSTX) Change in Account Payables (2023 - 2025) Analysis & Trends
OS Therapies (OSTX) has 3 years of Change in Account Payables data on file, last reported at $6.6 million in Q4 2025.
- Quarterly Change in Account Payables rose 6071.13% year-over-year to $6.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $8.3 million (up 885.54% YoY) and the FY2025 annual result came in at $8.3 million, up 885.54% from the prior year.
- Change in Account Payables advanced to $6.6 million in Q4 2025, from $671563.0 in the prior quarter.
- In the past five years, Change in Account Payables ranged from a high of $6.6 million in Q4 2025 to a low of -$897529.0 in Q3 2024.
- A 3-year average of $714048.9 and a median of $136363.5 in 2023 frame the typical range for Change in Account Payables.
- Annual changes were most pronounced in 2024 — Change in Account Payables sank 535.08% — and 2025, when it jumped 6071.13%.
- Tracing OSTX's Change in Account Payables over 3 years: stood at $231274.0 in 2023, then tumbled by 147.52% to -$109897.0 in 2024, then jumped by 6071.13% to $6.6 million in 2025.
- The last three Change in Account Payables figures came in at $6.6 million (Q4 2025), $671563.0 (Q3 2025), and $1.1 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | OS Therapies | 19.46 Mn | 19.46 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 6.56 Mn |
| Dec 31, 2025 | 6.56 Mn |
| Sep 30, 2025 | 671,563.00 |
| Sep 30, 2025 | 671,563.00 |
| Jun 30, 2025 | 1.09 Mn |
| Jun 30, 2025 | 1.09 Mn |
| Mar 31, 2025 | -45,678.00 |
| Mar 31, 2025 | -45,678.00 |
| Dec 31, 2024 | -109,897.00 |
| Dec 31, 2024 | -109,897.00 |
| Sep 30, 2024 | -897,529.00 |
| Sep 30, 2024 | -897,529.00 |
| Jun 30, 2024 | -87,358.00 |
| Jun 30, 2024 | -87,358.00 |
| Mar 31, 2024 | 41,453.00 |
| Mar 31, 2024 | 41,453.00 |
| Dec 31, 2023 | 231,274.00 |
| Dec 31, 2023 | 231,274.00 |
| Sep 30, 2023 | -141,326.00 |
| Sep 30, 2023 | -141,326.00 |